Clarivate Epidemiology’s coverage of diabetic neuropathy comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…
Clarivate Epidemiology’s coverage of diabetic neuropathy comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key diabetic neuropathy patient populations covering 171 countries and…
Clarivate Epidemiology’s coverage of diabetic neuropathy comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…
Clarivate Epidemiology’s coverage of diabetic neuropathy comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…
Clarivate Epidemiology’s coverage of diabetic neuropathy comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…
Clarivate Epidemiology’s coverage of diabetic neuropathy comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…
Clarivate Epidemiology's coverage of painful diabetic neuropathy (PDN) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…
DRG Epidemiology’s coverage of diabetic neuropathy comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of diabetic neuropathy for…
Painful diabetic neuropathy (PDN) in the United States is defined as having had numbness, loss of feeling, or painful sensations in the feet within the last three months. PDN is managed by multiple…
Painful diabetic neuropathy (PDN) in the United States is defined as having had numbness, loss of feeling, or painful sensations in the feet within the last three months. PDN is managed by multiple…
Painful diabetic neuropathy (PDN), a subset of diabetic neuropathy; affects approximately seven million people in the United States and major European markets. The primary goal of treating PDN is…
Using national patient-level claims data, this report analyzes physician adherence to the treatment guidelines by exploring the use of key therapies in the newly diagnosed and recently treated…
In 2013, painful diabetic neuropathy (PDN) affected more than 3.4 million people in the United States. Similar to postherpetic neuralgia, PDN has also served—and continues to serve—as a gateway…
In an Increasingly Generic Market, Replete with Well-Established Oral Therapies, What Drug Development Opportunities Remain? In 2012, painful diabetic neuropathy (PDN) affected more than 7.4…